Despite several alternative treatment modalities, such as CDK4/6-inhibitors (introduced in 2017 in Danish practice), having surfaced over the years for ER-positive advanced breast cancer patients, there is still a use of capecitabine as first-line therapy. This evidence concerns the gene CDK4 and breast carcinoma.